

References: L11493, A23902 (prior to 10/01/2015); L33800, A52517 (on/after 10/01/2015)

Respiratory Assist Devices (RAD) E0470 and E0471

- Face-to-Face Examination (F2F)
 - Date stamp indicating supplier's date of receipt of F2F on or before date of delivery
- Written Order Prior to Delivery (WOPD)
 - Date stamp indicating supplier's date of receipt of WOPD on or before date of delivery

All RAD Accessories and Supplies

- Dispensing Order, if applicable
- Detailed Written Order (DWO)
- Refill Requirements

All Devices, Accessories, and Supplies

- Proof of Delivery (POD)
 - Method 1 - Direct Delivery to the Beneficiary by the Supplier
The date the beneficiary/designee signs for the equipment or supplies is to be the date of service of the claim.
 - Method 2 - Delivery via Shipping or Delivery Service
The shipping date is to be the date of service of the claim.
- Continued Need
- Continued Use

Medical Records

- For initial coverage (first three (3) months of therapy), medical records must document:
 - Symptoms characteristic of sleep-associated hypoventilation i.e.:
 - Daytime hypersomnolence;
 - Excessive fatigue;
 - Morning headache;
 - Cognitive dysfunction;
 - Dyspnea, etc.; **and**
 - Beneficiary has one (1) of the following disorders and meets all coverage criteria for that disorder.

Restrictive Thoracic Disorder

- Medical records document:
 - Progressive neuromuscular disease (i.e. amyotrophic lateral sclerosis) or a severe thoracic cage abnormality (i.e. post-thoracoplasty for TB); **and**
 - Arterial blood gas PaCO₂, done while awake and breathing the usual FIO₂, is ≥ 45 mm Hg; **or**
 - Sleep oximetry demonstrates oxygen saturation $\leq 88\%$ for ≥ 5 minutes of nocturnal recording time (minimum recording time of 2 hours), done while breathing the beneficiary's prescribed recommended FIO₂; **or**
 - For a neuromuscular disease only, maximal inspiratory pressure is < 60 cm H₂O or forced vital capacity is $< 50\%$ predicted; **and**
 - Chronic Obstructive Pulmonary Disease (COPD) does not contribute significantly to the beneficiary's pulmonary limitation.

Severe COPD – E0470

- Medical records document:
 - Arterial blood gas PaCO₂ is ≥ 52 mm Hg while beneficiary is awake and breathing the prescribed FIO₂; **and**
 - Sleep oximetry study demonstrates oxygen saturation $\leq 88\%$ for ≥ 5 cumulative minutes of nocturnal recording time (minimum recording time of 2 hours), done while breathing oxygen at 2 LPM or the beneficiary's usual FIO₂ (whichever is higher); **and**
 - Prior to initiating therapy, obstructive sleep apnea (OSA) and treatment with a CPAP has been considered and ruled out.

Severe COPD – E0471

- Situation one: An E0471 started any time after a period of initial use of E0470 is covered if:
 - An arterial blood gas PaCO₂, done while awake and breathing the beneficiary's prescribed FIO₂, shows the beneficiary's PaCO₂ worsens ≥ 7 mm Hg compared to original result above; **and**
 - A facility based polysomnogram (PSG) demonstrates oxygen saturation $\leq 88\%$ for ≥ 5 cumulative minutes of nocturnal recording time (minimum recording time of 2 hours) while using an E0470 that is not caused by obstructive upper airway events (AHI < 5).
- Situation two: An E0471 will be covered no sooner than 61 days after initial issue of the E0470 if:
 - An arterial blood gas PaCO₂ is done while awake and breathing the beneficiary's prescribed FIO₂, still remains ≥ 52 mm Hg; **and**
 - Sleep oximetry while breathing with the E0470 demonstrates oxygen saturation $\leq 88\%$ for ≥ 5 cumulative minutes of nocturnal recording time (minimum recording time of 2 hours), done while breathing oxygen at 2 LPM or the beneficiary's prescribed FIO₂ (whichever is higher).

Central Sleep or Complex Sleep Apnea

- Prior to initiating therapy, a complete facility-based, attended PSG was performed documenting:
 - Diagnosis of either central (CSA) or complex sleep apnea (CompSA); **and**
 - Significant improvement of the sleep-associated hypoventilation with use of an E0470 or E0471 on the settings the physician prescribed for initial use at home while breathing the usual FIO₂.

Hypoventilation Syndrome

- E0470 is covered if the medical records support:
 - An initial arterial blood gas PaCO₂, done while awake and breathing the beneficiary's prescribed FIO₂, is ≥ 45 mm Hg; **and**
 - Spirometry shows an FEV₁/FVC $\geq 70\%$ and an FEV₁ $\geq 50\%$ of predicted; **and**
 - An arterial blood gas PaCO₂, done during sleep or immediately upon awakening, and while breathing the beneficiary's prescribed FIO₂, shows the beneficiary's PaCO₂ worsened ≥ 7 mm Hg compared to the original result; **or**
 - A facility based PSG or home sleep testing (HST) demonstrates oxygen saturation $\leq 88\%$ for ≥ 5 minutes of nocturnal recording (minimum recording time of 2 hours) that is not caused by obstructive upper airway events (AHI < 5).
- E0471 is covered if the medical records support:
 - A covered E0470 is being used; **and**
 - Spirometry shows an FEV₁/FVC $\geq 70\%$ and an FEV₁ $\geq 50\%$ of predicted; **and**
 - An arterial blood gas PaCO₂, done while awake and breathing the beneficiary's prescribed FIO₂, shows the beneficiary's PaCO₂ worsens ≥ 7 mm Hg compared to the ABG result performed to qualify the patient for the E0470 device; **or**
 - A facility based PSG or HST demonstrates oxygen saturation $\leq 88\%$ for ≥ 5 minutes of nocturnal recording time (minimum recording time of 2 hours) that is not caused by obstructive upper airway events (AHI < 5 while using an E0470).

Continued Coverage (Beyond the First Three Months of Therapy) - E0470 or E0471

- Medical records document beneficiary was re-evaluated on/after the 61st day of therapy
 - Progress of relevant symptoms; **and**
 - Beneficiary usage of the device (average 4 hours per 24 hours)
- Documentation in supplier's records:
 - Signed and dated physician statement completed no sooner than 61 days after initiating use of the device declaring:
 - Beneficiary is consistently using device an average of 4 hours per 24 hour period; **and**
 - Beneficiary is benefiting from its use.

Replacement of an E0470 or E0471

- Following the 5 year reasonable useful lifetime (RUL), there must be a F2F that documents the beneficiary continues to use and benefit from the device; **and**
- A new prescription is required

Beneficiaries Entering Medicare

- Qualification test – Documentation that the beneficiary had testing prior to FFS Medicare enrollment, that meets the current coverage criteria in effect at the time that the beneficiary seeks Medicare coverage of a replacement device and/or accessory; **and**
- Clinical Evaluation – Following enrollment in FFS Medicare, the beneficiary must have a F2F documenting all of the following:

- Beneficiary has the qualifying medical condition for the applicable scenario; **and**
- Testing performed, date of the testing used for qualification and results; **and**
- Beneficiary continues to use the device; **and**
- Beneficiary is benefiting from the treatment.

Ventilators with Noninvasive Interfaces (E0466)

- Medical records document on of the following conditions:
 - Neuromuscular disease
 - Thoracic restrictive disease
 - Chronic respiratory failure consequent to COPD; **and**
- Condition is life-threatening where interruption of respiratory support would quickly lead to serious harm or death

Billing Reminders

- Add the KX modifier to all claims for RADs and accessories for the first through third months if all the coverage criteria have been met.
- Add the KX modifier to all claims for the fourth month and thereafter if all the coverage criteria have been met **and** if the physician signed and dated a statement declaring that the beneficiary is compliantly using and is benefiting from the device.
- The signed physician statement must be obtained and kept on file by the supplier for continued coverage beyond three months.
- The signed physician statement should not be sent in with the claim but must be available upon request.
- When there is an expectation of a medical necessity denial, the GA modifier must be added to the code if a valid Advance Beneficiary Notice (ABN) has been obtained or a GZ modifier if a valid ABN has not been obtained.
- Claims for ventilators (E0465, E0466) used for the treatment of conditions described in the RAD LCD will be denied as not reasonable and necessary.

[Print Form](#)

The content of this document was prepared as an education tool and is not intended to grant rights or impose obligations. Use of this document is not intended to take the place of either written law or regulations. Suppliers are reminded to review the Local Coverage Determination and Policy Article for specific documentation guidelines.

[Go Back to Front Page](#)